Overview

• The FDA will send a letter to clinicians about acetaminophen use in pregnancy and begin a safety-label update following the White House announcement.
• The administration highlighted leucovorin as a potential therapy for autism symptoms and said labeling updates are planned as research proceeds.
• Evidence remains mixed, with recent observational reviews reporting associations but a 2024 Swedish sibling-controlled study finding no causal effect.
• Kenvue and leading obstetric societies said science does not support a link to autism and warned that avoiding acetaminophen could harm pregnant patients.
• Kenvue shares fell during Monday trading after the announcement, and the NIH unveiled $50 million in new autism data research grants.